Table 1. Overall response and durability... | American Society of Hematology

Table 1.

Overall response and durability results per investigator

Results	n = 58	95% CI
Objective response (%)	86	74.6-93.9*
CR (%)	66	51.9-77.5*
Partial response (%)	21
Stable disease (%)	7
Progressive disease (%)	3
Not evaluable (%)†	3
Median duration of objective response (months)	25.6	11.8-NE‡
Median duration of response in patients with CR (months)	Not reached	20.0-NE‡
Median PFS (months)	20.0	9.4-NE‡
Median OS (months)	Not reached	21.3-NE‡

Results	n = 58	95% CI
Objective response (%)	86	74.6-93.9*
CR (%)	66	51.9-77.5*
Partial response (%)	21
Stable disease (%)	7
Progressive disease (%)	3
Not evaluable (%)†	3
Median duration of objective response (months)	25.6	11.8-NE‡
Median duration of response in patients with CR (months)	Not reached	20.0-NE‡
Median PFS (months)	20.0	9.4-NE‡
Median OS (months)	Not reached	21.3-NE‡

NE, not estimable.

Two-sided 95% exact CI computed using the F distribution method.¹⁸

Defined as patients determined to have systemic ALCL by local assessment, but not by central pathology review; scored as nonresponder per protocol.

Computed using the method of Brookmeyer and Crowley.¹⁹